Color Doppler Imaging Analysis of Retrobulbar Blood Flow Velocities in Primary Open-Angle Glaucomatous Eyes: A Meta-Analysis

Por Meng, Nana, Zhang, Ping, Huang, Huadong, Ma, Jinlan, Zhang, Yue, Li, Hao, Qu, Yi
Publicado em 2013

Overexpression of High Mobility Group A1 Protein in Human Uveal Melanomas: Implication for Prognosis

Por Qu, Yi, Wang, Yupeng, Ma, Jinlan, Zhang, Yue, Meng, Nana, Li, Hao, Wang, Yan, Wei, Wenbin
Publicado em 2013

YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models

Por Xu, Youzhi, Lin, Hongjun, Meng, Nana, Lu, Wenjie, Li, Guobo, Han, Yuanyuan, Dai, Xiaoyun, Xia, Yong, Song, Xiangrong, Yang, Shengyong, Wei, Yuquan, Yu, Luoting, Zhao, Yinglan
Publicado em 2013

A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Por Xu, Youzhi, Lu, Wenjie, Yang, Peng, Peng, Wen, Wang, Chunting, Li, Manli, Li, Yan, Li, Guobo, Meng, Nana, Lin, Hongjun, Kan, Lixin, Wang, Siying, Yang, Shengyong, Yu, Luoting, Zhao, YingLan
Publicado no BMC Cancer (2015)

YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Por Xia, Yong, Song, Xuejiao, Li, Deliang, Ye, Tinghong, Xu, Youzhi, Lin, Hongjun, Meng, Nana, Li, Guobo, Deng, Senyi, Zhang, Shuang, Liu, Li, Zhu, Yongxia, Zeng, Jun, Lei, Qian, Pan, Youli, Wei, Yuquan, Zhao, Yinglan, Yu, Luoting
Publicado em 2014